Guardant Health, Inc. announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024. The company reported preliminary full-year 2024 revenue growth of 31%, driven by strong clinical and biopharma volume and Guardant360 ASP tailwinds.
For the full year 2024, preliminary unaudited free cash flow was approximately negative $275 million. The company ended the year with approximately $944 million in cash, cash equivalents, restricted cash, and marketable debt securities as of December 31, 2024.
Helmy Eltoukhy, co-CEO, highlighted 2024 as an outstanding year, with key milestones achieved across the portfolio, including the upgrade of Guardant360 LDT onto the Smart Liquid Biopsy platform. AmirAli Talasaz, co-CEO, noted strong traction and support for Shield in its first full quarter of commercial launch.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.